Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
TNF Inhibitors
•
Cardiology
•
Cardio-Rheumatology
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Related Questions
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
How do you approach management of recurrent idiopathic pleuropericarditis?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
How do you approach cardiovascular risk management in patients with rheumatic disease?
Would you re-challenge a patient with Rituximab who responded well in terms of their RA but developed symptomatic tachycardia after their first infusion?
How do you approach choosing between subcutaneous and IV actemra for RA?
What is your approach to biologic therapy in older adults (80+) with RA and CKD?
Are there any recommendations for restarting JAKi after a provoked DVT?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
How do you approach the management of a patient with RA on methotrexate who has gingivitis or or frequent cavities?
